Literature DB >> 3293157

Ciprofloxacin: in vitro activity, mechanism of action, and resistance.

C C Sanders1.   

Abstract

Ciprofloxacin is a new fluoroquinolone that is highly active against many diverse microorganisms. At concentrations of less than 1 microgram/mL it is active against most gram-negative bacteria, including Enterobacteriaceae, Haemophilus, Neisseria, and other Pasteurellaceae, Vibrionaceae, and various species of Pseudomonas and Acinetobacter. Most staphylococci, including strains resistant to methicillin, are also susceptible to ciprofloxacin. Streptococci are not highly susceptible to ciprofloxacin, and obligate anaerobes are generally resistant to this and other quinolones. Ciprofloxacin, like other quinolones, inhibits DNA gyrase, but its bactericidal effects are not completely reversible by inhibitors of protein or RNA synthesis. Thus, unlike many other quinolones, ciprofloxacin may have multiple lethal effects. Resistance is less readily selected in vitro by ciprofloxacin than by nalidixic acid, and single-step mutants usually remain susceptible to clinically achievable concentrations. Resistance mediated by mutations in genes altering DNA gyrase and expression of outer membrane proteins has been described for ciprofloxacin and other quinolones. The antimicrobial spectrum and potency of ciprofloxacin, coupled with its rapid bactericidal effects, make this fluoroquinolone a promising new antimicrobial agent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3293157     DOI: 10.1093/clinids/10.3.516

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  21 in total

1.  The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis).

Authors:  S P Saini; A K Srivastava
Journal:  Vet Res Commun       Date:  2001-12       Impact factor: 2.459

2.  Arrested protein synthesis increases persister-like cell formation.

Authors:  Brian W Kwan; John A Valenta; Michael J Benedik; Thomas K Wood
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

3.  A data-based mathematical modelling study to quantify the effects of ciprofloxacin and ampicillin on the within-host dynamics of Salmonella enterica during treatment and relapse.

Authors:  Myrto Vlazaki; Omar Rossi; David J Price; Callum McLean; Andrew J Grant; Pietro Mastroeni; Olivier Restif
Journal:  J R Soc Interface       Date:  2020-07-08       Impact factor: 4.118

Review 4.  Modulation of the host flora.

Authors:  R van Furth; H F Guiot
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-01       Impact factor: 3.267

5.  In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  The Global Regulatory Cyclic AMP Receptor Protein (CRP) Controls Multifactorial Fluoroquinolone Susceptibility in Salmonella enterica Serovar Typhimurium.

Authors:  Stefani C Kary; Joshua R K Yoneda; Stephen C Olshefsky; Laura A Stewart; Steven B West; Andrew D S Cameron
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

7.  Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.

Authors:  E A Gorzynski; D Amsterdam; T R Beam; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.

Authors:  T Kocagöz; C J Hackbarth; I Unsal; E Y Rosenberg; H Nikaido; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria.

Authors:  P Heisig; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

10.  Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis.

Authors:  M Dan; Y Siegman-Igra; S Pitlik; R Raz
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.